Leading Companies Accelerating Clinical Trials with Veeva Vault CDMS
12.10.2020 14:03:00 EEST | Business Wire | Press release
Veeva Systems (NYSE: VEEV) today announced that an increasing number of companies are adopting Veeva Vault CDMS to manage their clinical data. More emerging biotechs and global organizations, including a second top 20 pharmaceutical company, are modernizing clinical data management with Vault CDMS and starting studies faster. Vault CDMS has been used in over 100 trials, for studies in all phases and across diverse therapeutic areas.
Vault CDMS is a modern cloud application suite that combines EDC, coding, data cleaning, and reporting. Customers are building study databases in less than four weeks and making mid-study amendments with zero downtime to run the trials they want without technology limitations.
New innovative capabilities such as configuring rules for edit checks and updating reference ranges across all studies reduce manual processes and provide faster, more precise ways of building and managing trial data. Companies can now accelerate trial database builds, improve efficiency for study teams, and increase consistency in data management across CRO providers.
“Veeva Vault CDMS is helping organizations keep pace with the complexity of today’s clinical trial,” said Henry Levy, general manager, Vault CDMS, site, and patient solutions at Veeva. “Companies are standardizing on Veeva’s clinical data management suite for a fundamentally new approach to building studies and cleaning data.”
At the upcoming Veeva R&D & Quality Summit, Oct. 13-14, 2020, leading organizations will discuss how standardizing on Vault CDMS helps them build and clean studies faster and more efficiently, including:
- Eli Lilly and Company modernizing their data management infrastructure to aggregate all study data for centralized data cleaning and transformation.
- Alcon supporting rapid study start-ups that are crucial for the quick development cycles of medical device products.
- Parker Institute of Cancer Immunotherapy handling the demands of highly complex studies that legacy systems struggle to support.
Vault CDMS is part of Veeva Vault Clinical Suite, the industry’s first cloud platform that unifies clinical data management and clinical operations. More than 300 companies are using Veeva clinical applications, including 45 sponsors using Veeva Vault EDC.
Veeva R&D & Quality Summit is an online event open to life sciences industry professionals. Register and view the agenda at veeva.com/Summit.
Additional Information
For more on Veeva Vault CDMS, visit: veeva.com/VaultCDMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005220/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports Full Year and Fourth Quarter 2025 Results12.2.2026 08:01:00 EET | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211688662/en/ Figure 14. Terms and debt repayment schedule as of 31 December 2025 (billion USD) Regulated and inside information1 “Beer plays an important role in bringing people together and creating moments of celebration. In 2025, we executed our strategy, made disciplined capital allocation choices and delivered growth within our outlook for the year, even as we navigated a dynamic consumer environment. We exit 2025 with improved momentum and enter 2026 well positioned to engage consumers with our megabrands and an unparalleled lineup of mega platforms. Thank you to our colleagues for their ongoing commitment, hard work and passion for our business.” – Michel Doukeris, CEO, AB InBev Revenue 4Q +2.5% | FY +2.0% Revenue increased by 2.5% in 4Q25 with revenue per hl growth of 4.0% and by 2.0% in FY25 with rev
Bardasz Forms Strategic Digital Alliance with GEOLOG to Accelerate Global RTOC Delivery and Digital Well Construction Solutions12.2.2026 08:00:00 EET | Press release
Bardasz Group LLC (“Bardasz”), a provider of real-time, decision-ready intelligence for well construction—including drilling, completions, and well interventions—today announced a strategic digital alliance with GEOLOG International B.V. (“GEOLOG”), a global formation evaluation, drilling, and geochemistry services provider supporting subsurface projects in more than 40 countries. The alliance is designed to accelerate Bardasz’s global growth and enhance customer delivery by leveraging GEOLOG’s in-country resources, technical expertise, and operational scale. Bardasz helps operators transform fragmented well construction data into actionable intelligence across assets—enabling faster integration, increased reliability of real-time data workflows, and improved rig-time efficiency with reduced non-productive time (NPT). Bardasz’s high-frequency real-time well construction platform is built on best-in-class WITSML and ETP standards and is engineered for scaled, enterprise-grade environmen
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties12.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients – who were all new to injectable aesthetics – over two years.1 This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and demonstrate how Sculptra adapts to different skin types, life stages, and aesthetic goals.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211375008/en/ Sculptra is the first proven regenerative biostimulator, backed by over 25 years of clinical use.2-6 With a unique poly-L-lactic acid (PLLA-SCA™) formulation, Sculptra re-engages the skin’s renewal process, stimulating collagen and elastin for healthy looking skin.3,7-11 Over the decades, it has evolved into a versatile treatment that delivers regenerati
Lenovo Group: Third Quarter Financial Results 2025/2612.2.2026 06:13:00 EET | Press release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported results for the third quarter of fiscal year 2025/26, a quarter that delivered record revenues, accelerated profitability, and continued AI revenue expansion. During the quarter, overall group revenue reached an all-time fiscal quarter high of US$22.2 billion, up 18% year-on-year, with revenue from all business groups growing double-digit year-on-year. Excluding non-operating non-cash items and one-time gains and charges in Q3 FY24/25 and Q3 FY25/26, adjusted net income (profit attributable to equity holders – non-HKFRS)[1] increased by 36% year-on-year to US$589 million, with adjusted net income margin[1] expanding to 2.7%. The results demonstrate the Group’s ability to deliver on its promise of double-digit growth and sustained profitability, while proving its ability to manage through cycles by leveraging innovation to drive growth and operational excellence to navigate volatil
IFF Reports Fourth Quarter and Full Year 2025 Results11.2.2026 23:36:00 EET | Press release
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Management Commentary “IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment,” said Erik Fyrwald, CEO of IFF. “It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.” “We also took steps to optimize our portfolio. Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improved our financial flexibility, allowing us to direct resources to our highest-value businesses.” “Looking ahead to 2026, we are continuing to serve our customers with leading innovation to grow
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom